The reevaluation at 12 months showed impairment of pituitary function in 21.4% (3 out of 14) of patients after HP and in 9.1% (1 out of 11) after SAH.
Endurmat eftir 12 mánuði sýndi fram á vanstarfsemi hjá 21,4% (3 af 14) eftir HÁ og hjá 9,1% (1 af 11) eftir IB.